Impact Factor 2020: 1.226 (@Clarivate Analytics)
5-Year Impact Factor: 2.285 (@Clarivate Analytics)
Immediacy Index: 2.645
  • Users Online: 2745
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2021  |  Volume : 14  |  Issue : 10  |  Page : 433-439

Favipiravir and its potentials in COVID-19 pandemic: An update


1 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Asia Shine Trading & Service CO. LTD., Ho Chi Minh City 700000, Vietnam
2 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Essen Healthcare, Bronx, New York 10461 USA
3 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Department of Internal Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam
4 American University of the Caribbean, Cupecoy, Sint Maarten
5 Institute of Fundamental and Applied Sciences, Duy Tan University, Ho Chi Minh City 700000; Faculty of Natural Sciences, Duy Tan University, Da Nang City 550000, Vietnam
6 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Department of Otorhinolaryngology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
7 Online Research Club, School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan; Methodist Hospital, Merrillville, Indiana, United States
8 School of Tropical Medicine and Global Health, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
9 Department of International Trials, Center of Clinical Sciences, National Center for Global Health and Medicine (NCGM), Tokyo, Japan

Correspondence Address:
Nguyen Tien Huy
School of Tropical Medicine and Global Health, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523
Japan
Login to access the Email id

Source of Support: This study was funded by the Japan Agency for Medical Research and Development (AMED) under Grant Asian clinical trial network construction project (Number JP20lk0201001j0001). The funders had no role in preparation of the manuscript., Conflict of Interest: None


DOI: 10.4103/1995-7645.329005

Get Permissions

The COVID-19 pandemic has caused millions of deaths and hundreds of millions of confirmed infections worldwide. This pandemic has prompted researchers to produce medications or vaccines to reduce or stop the progression and spread of this disease. A variety of previously licensed and marketed medications are being tested for the treatment and recurrence of SARS-CoV2, including favipiravir (Avigan). Favipiravir was recognized as an influenza antiviral drug in Japan in 2014, and has been known to have a potential in vitro activity against SARS-CoV-2, in addition to its broad therapeutic safety scope. Favipiravir was recently approved and officially used in many countries worldwide. Our review provides insights and up-to-date knowledge of the current role of favipiravir in the treatment of COVID-19 infection, focusing on pre-clinical and ongoing clinical trials, evidence of its efficacy against SARS-CoV-2 in COVID-19, side effects, anti-viral mechanism, and the pharmacokinetic properties of the drug in the treatment of COVID-19. Due to its teratogenic effects, favipiravir cannot be offered to expectant or pregnant mothers. The practical efficacy of such an intervention regimen will depend on its dose, treatment duration, and cost as well as difficulties in application.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed610    
    Printed8    
    Emailed0    
    PDF Downloaded139    
    Comments [Add]    

Recommend this journal